Related Experiment Video
Updated: Feb 28, 2026
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient Populations
Emre Yücel1, Alex Soriano2, Florian Thalhammer3
1Merck & Co., Inc., P.O. Box 1000, Rahway, NJ 07065, USA.
Abstract:
Background: AMR is a public health concern which leads to high global morbidity and mortality. Immunocompromised patients, who are more susceptible to contracting potentially life-threatening infections, are faced with reduced treatment options due to emerging AMR. Ceftolozane/tazobactam is a novel β-lactam/β-lactamase inhibitor which displays effectiveness against resistant Gram-negative infections. Methods: SPECTRA was a multinational, observational study conducted in seven countries including 617 patients who received ≥48 h of ceftolozane/tazobactam. Medical-record data were collected up to 6 months before treatment and 30 days after the final dose or until death. This analysis describes clinical outcomes and healthcare resource use in patients with sepsis or who were immunocompromised, specifically in patients with hematologic malignancy with and without solid tumor, febrile neutropenia, and solid organ transplant patients. Results: Clinical success ranged from 50.0% in patients with hematologic malignancy and solid tumor to 69.4% in 38 patients with febrile neutropenia. All-cause in-hospital mortality was 23.1-42.9%, with the lowest rates in patients with solid organ transplant. ICU admission was 46.4-68.2% across subpopulations (excluding febrile neutropenia) with the lowest rates in patients with hematologic malignancy. ICU length of stay was lowest within transplant patients (9 days) and highest within the hematologic malignancy and solid tumor population (32 days). Conclusions: The results from this sub analysis of SPECTRA showed that ceftolozane/tazobactam was associated with clinical success in the selected immunocompromised and sepsis patient populations and may lead to reduced morbidity, mortality, and healthcare-resource use. Further research is required to standardize treatment protocols and improve patient outcomes.
Insights
Ceftolozane/tazobactam demonstrated clinical success in immunocompromised patients with sepsis, potentially reducing mortality and healthcare use. Further research is needed to optimize treatment protocols for these vulnerable populations.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- Antimicrobial resistance (AMR) poses a significant global health threat, increasing morbidity and mortality.
- Immunocompromised patients face limited treatment options for life-threatening infections due to emerging AMR.
- Ceftolozane/tazobactam is a novel antimicrobial agent effective against resistant Gram-negative bacteria.
Purpose of the Study:
- To evaluate the clinical outcomes and healthcare resource utilization of ceftolozane/tazobactam in immunocompromised patients with sepsis.
- To analyze treatment effectiveness across specific immunocompromised subpopulations: hematologic malignancy, febrile neutropenia, and solid organ transplant recipients.
Main Methods:
- The SPECTRA study was a multinational observational trial involving 617 patients receiving ceftolozane/tazobactam for at least 48 hours.
- Medical records were analyzed for clinical outcomes and healthcare resource use up to 6 months pre-treatment and 30 days post-treatment.
- Subgroup analysis focused on patients with sepsis or who were immunocompromised, including those with hematologic malignancy, febrile neutropenia, and solid organ transplants.
Main Results:
- Clinical success rates varied by subgroup, ranging from 50.0% in patients with hematologic malignancy and solid tumor to 69.4% in febrile neutropenia patients.
- All-cause in-hospital mortality ranged from 23.1% to 42.9%, with the lowest rates observed in solid organ transplant recipients.
- Intensive Care Unit (ICU) admission rates were 46.4-68.2% (excluding febrile neutropenia), and ICU length of stay was lowest in transplant patients (9 days) and highest in the hematologic malignancy and solid tumor group (32 days).
Conclusions:
- Ceftolozane/tazobactam showed clinical success in immunocompromised patients with sepsis.
- The study suggests potential benefits in reducing morbidity, mortality, and healthcare resource consumption.
- Further research is recommended to standardize treatment protocols and enhance patient outcomes in these vulnerable groups.
Related Concept Videos
01:28Antimicrobial Effectiveness
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...